Organization
Catalyst Pharmaceuticals
4 clinical trials
Clinical trial
Long Term Safety Study of Amifampridine Phosphate in Patients With MuSK Antibody Positive and AChR (Acetylcholine Receptor) Antibody Positive Myasthenia GravisStatus: Terminated, Estimated PCD: 2022-08-05
Clinical trial
A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis PatientsStatus: Completed, Estimated PCD: 2020-01-31
Clinical trial
Long Term Safety Study of Amifampridine Phosphate in Ambulatory Patients With Spinal Muscular Atrophy (SMA) Type 3Status: Terminated, Estimated PCD: 2021-09-13